Questcor Pharmaceuticals Company Profile (NASDAQ:QCOR)

About Questcor Pharmaceuticals

Questcor Pharmaceuticals logoQuestcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications; the investigation of other potential uses of Acthar for indications not FDA approved; and the expansion of its understanding of how Acthar works in the human body (pharmacology), and ultimately, its mechanisms of action in the disease states for which it is used, or may be used in the future. The Company sells Doral to pharmaceutical wholesalers, which resell Doral primarily to retail pharmacies and hospitals.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: QCOR
  • CUSIP: 74835Y10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $92
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 12.73
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to Questcor Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Questcor Pharmaceuticals (NASDAQ:QCOR) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Questcor Pharmaceuticals (NASDAQ:QCOR)
No equities research coverage for this company has been tracked by


Earnings History for Questcor Pharmaceuticals (NASDAQ:QCOR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2014Q214$1.74$1.85$261.02 million$278.80 millionViewN/AView Earnings Details
4/28/2014Q114$1.61$1.40$239.81 million$227.10 millionViewN/AView Earnings Details
2/25/2014Q413$1.66$1.67$244.15 million$243.00 millionViewN/AView Earnings Details
10/29/2013Q313$1.29$1.52$199.70 million$236.35 millionViewN/AView Earnings Details
7/30/2013Q2 2013$0.96$1.12$168.96 million$184.60 millionViewN/AView Earnings Details
4/30/2013Q1 2013$0.96$0.76$157.68 million$135.13 millionViewN/AView Earnings Details
2/26/2013Q4 2012$0.90$1.03$142.58 million$160.50 millionViewN/AView Earnings Details
10/23/2012$0.74$0.91ViewN/AView Earnings Details
7/24/2012$0.63$0.65ViewN/AView Earnings Details
2/22/2012$0.41$0.47ViewN/AView Earnings Details
10/25/2011$0.26$0.37ViewN/AView Earnings Details
4/26/2011$0.17$0.20ViewN/AView Earnings Details
2/23/2011$0.15$0.12ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Questcor Pharmaceuticals (NASDAQ:QCOR)
Current Year EPS Consensus Estimate: $6.73 EPS
Next Year EPS Consensus Estimate: $7.35 EPS


Dividend History for Questcor Pharmaceuticals (NASDAQ:QCOR)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Questcor Pharmaceuticals (NASDAQ:QCOR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/13/2014Don M BaileyInsiderSell40,000$91.96$3,678,400.00View SEC Filing  
8/11/2014Michael H MulroyInsiderSell10,000$92.33$923,300.00View SEC Filing  
7/14/2014Don M BaileyInsiderSell40,000$95.54$3,821,600.00View SEC Filing  
7/10/2014Michael H MulroyInsiderSell10,000$90.89$908,900.00View SEC Filing  
6/24/2014David YoungInsiderSell6,000$91.96$551,760.00View SEC Filing  
6/13/2014Don M BaileyCEOSell40,000$89.83$3,593,200.00View SEC Filing  
6/10/2014Michael H MulroyInsiderSell10,000$88.57$885,700.00View SEC Filing  
5/19/2014David Jeffrey MedeirosEVPSell2,292$89.66$205,500.72View SEC Filing  
5/13/2014Don BaileyCEOSell40,000$87.05$3,482,000.00View SEC Filing  
5/12/2014Michael MulroyInsiderSell10,000$87.99$879,900.00View SEC Filing  
4/21/2014David Jeffrey MedeirosEVPSell2,292$77.15$176,827.80View SEC Filing  
4/14/2014Don BaileyCEOSell40,000$79.65$3,186,000.00View SEC Filing  
4/10/2014Michael MulroyInsiderSell10,000$85.04$850,400.00View SEC Filing  
4/7/2014Stephen FarrellDirectorSell10,000$81.43$814,300.00View SEC Filing  
3/17/2014David Jeffrey MedeirosEVPSell2,291$62.61$143,439.51View SEC Filing  
3/14/2014David YoungInsiderSell6,000$62.28$373,680.00View SEC Filing  
3/13/2014Don BaileyCEOSell40,000$62.71$2,508,400.00View SEC Filing  
3/10/2014Michael MulroyInsiderSell10,000$64.80$648,000.00View SEC Filing  
2/25/2014Broadwood Partners LpDirectorSell83,600$79.59$6,653,724.00View SEC Filing  
2/20/2014Broadwood Partners LpDirectorSell306,400$74.94$22,961,616.00View SEC Filing  
2/12/2014Broadwood Partners LpDirectorSell85,000$69.10$5,873,500.00View SEC Filing  
1/30/2014Broadwood Partners LpDirectorSell50,000$66.55$3,327,500.00View SEC Filing  
1/24/2014David YoungInsiderSell6,000$64.38$386,280.00View SEC Filing  
1/23/2014Broadwood Partners LpDirectorSell20,000$65.00$1,300,000.00View SEC Filing  
1/23/2014David Jeffrey MedeirosEVPSell133,541$64.91$8,668,146.31View SEC Filing  
1/16/2014David Jeffrey MedeirosEVPSell50,000$62.00$3,100,000.00View SEC Filing  
1/13/2014Don BaileyCEOSell40,000$53.64$2,145,600.00View SEC Filing  
11/14/2013Neal BradsherDirectorSell40,000$62.41$2,496,400.00View SEC Filing  
11/13/2013Broadwood Partners LpDirectorSell500,000$62.37$31,185,000.00View SEC Filing  
10/14/2013Don BaileyCEOSell40,000$62.16$2,486,400.00View SEC Filing  
10/14/2013Virgil ThompsonDirectorSell2,500$60.50$151,250.00View SEC Filing  
9/16/2013Virgil ThompsonDirectorSell5,000$63.75$318,750.00View SEC Filing  
9/13/2013Don BaileyCEOSell40,000$63.69$2,547,600.00View SEC Filing  
8/26/2013David Jeffrey MedeirosEVPSell55,000$73.98$4,068,900.00View SEC Filing  
8/14/2013Virgil ThompsonDirectorSell5,000$69.12$345,600.00View SEC Filing  
8/13/2013David Jeffrey MedeirosEVPSell110,597$67.85$7,504,006.45View SEC Filing  
8/6/2013David Jeffrey MedeirosEVPSell58,831$66.69$3,923,439.39View SEC Filing  
7/15/2013Don M BaileyCEOSell33,339$49.31$1,643,946.09View SEC Filing  
7/15/2013Virgil D ThompsonDirectorSell5,000$49.29$246,450.00View SEC Filing  
6/14/2013Virgil D ThompsonDirectorSell5,000$45.55$227,750.00View SEC Filing  
6/13/2013Don M BaileyCEOSell40,000$45.01$1,800,400.00View SEC Filing  
5/14/2013Don M BaileyCEOSell180,000$40.14$7,225,200.00View SEC Filing  
5/14/2013Virgil D ThompsonDirectorSell5,000$37.46$187,300.00View SEC Filing  
5/9/2013Virgil D ThompsonDirectorSell2,187$35.00$76,545.00View SEC Filing  
3/21/2013Virgil D ThompsonDirectorSell47,500$35.00$1,662,500.00View SEC Filing  
11/5/2012David Jeffrey MedeirosEVPBuy55,000$23.92$1,315,600.00View SEC Filing  
11/2/2012Stephen Lahue CarttVPBuy10,000$24.17$241,700.00View SEC Filing  
9/4/2012Mitchell J Md BluttDirectorSell24,730$47.60$1,177,148.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Questcor Pharmaceuticals (NASDAQ:QCOR)
News IconAetna Member Services Phone Numbers & Customer Service Helpline Support - The Voice Observer (blog) (NASDAQ:QCOR) - January 16 at 3:55 PM logoMallinckrodt’s Questcor Said Facing Multistate Antitrust Probe (NASDAQ:QCOR) - June 17 at 6:46 PM logoMallinckrodt Tops Q2 Earnings & Revenues on Acquisitions - Analyst Blog (NASDAQ:QCOR) - May 5 at 1:30 PM logoMallinckrodt shares rise on earnings outlook (NASDAQ:QCOR) - October 14 at 10:07 AM logoMS drug sales drive Questcor profit (NASDAQ:QCOR) - July 24 at 9:28 AM logoUpdate-Moody's assigns Ba2 to Mallinckrodt's new sr. secured term loan (NASDAQ:QCOR) - July 15 at 9:29 AM


Questcor Pharmaceuticals (NASDAQ:QCOR) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff